BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7494899)

  • 1. Neurotoxicity modeling for risk assessment.
    Kodell RL; Chen JJ; Gaylor DW
    Regul Toxicol Pharmacol; 1995 Aug; 22(1):24-9. PubMed ID: 7494899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
    Hasegawa R; Koizumi M; Hirose A
    Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Background to the ADI/TDI/PTWI.
    Herrman JL; Younes M
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision of estimates of an ADI (or TDI or PTWI).
    Speijers GJ
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative risk assessment for developmental neurotoxic effects.
    Razzaghi M; Kodell R
    Risk Anal; 2004 Dec; 24(6):1673-81. PubMed ID: 15660620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotoxicology dose/response assessment for several cholinesterase inhibitors: use of uncertainty factors.
    Raffaele KC; Rees C
    Neurotoxicology; 1990; 11(2):237-56. PubMed ID: 2234543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A probabilistic framework for non-cancer risk assessment.
    Chen JJ; Moon H; Kodell RL
    Regul Toxicol Pharmacol; 2007 Jun; 48(1):45-50. PubMed ID: 17166641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedures for calculating benchmark doses for health risk assessment.
    Gaylor D; Ryan L; Krewski D; Zhu Y
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-cancer risk assessment for nickel compounds: issues associated with dose-response modeling of inhalation and oral exposures.
    Haber LT; Allen BC; Kimmel CA
    Toxicol Sci; 1998 Jun; 43(2):213-29. PubMed ID: 9710963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk assessment for neurotoxic effects.
    Gaylor DW; Slikker W
    Neurotoxicology; 1990; 11(2):211-8. PubMed ID: 1700346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A procedure for developing risk-based reference doses.
    Gaylor DW; Kodell RL
    Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantalization of continuous data for benchmark dose estimation.
    Gaylor DW
    Regul Toxicol Pharmacol; 1996 Dec; 24(3):246-50. PubMed ID: 8975754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health assessment of phosgene: approaches for derivation of reference concentration.
    Gift JS; McGaughy R; Singh DV; Sonawane B
    Regul Toxicol Pharmacol; 2008 Jun; 51(1):98-107. PubMed ID: 18440110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the acceptable daily intake as presently used an axiom or a dogma?
    Galli CL; Marinovich M; Lotti M
    Toxicol Lett; 2008 Aug; 180(2):93-9. PubMed ID: 18588960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A parametric model for detecting hormetic effects in developmental toxicity studies.
    Hunt DL; Bowman D
    Risk Anal; 2004 Feb; 24(1):65-72. PubMed ID: 15028001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current state of knowledge on the use of the benchmark dose concept in risk assessment.
    Sand S; Victorin K; Filipsson AF
    J Appl Toxicol; 2008 May; 28(4):405-21. PubMed ID: 17879232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future of toxicology--low-dose toxicology and risk--benefit analysis.
    Rietjens IM; Alink GM
    Chem Res Toxicol; 2006 Aug; 19(8):977-81. PubMed ID: 16918235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.